PubMed Trending Research Digest — June 17, 2026

Automated digest · 97 articles · 20 research areas · June 17, 2026

Overview

This week’s digest is dominated by two cross-cutting trends: (1) precision and mechanism-informed oncology, and (2) evidence synthesis and risk stratification to translate complex data into clinical decisions. In oncology, multiple studies advance targeted strategies and their biological underpinnings—ranging from EGFR-mutated NSCLC consolidation/first-line optimization to KRASG12D vulnerabilities (e.g., WFS1, ISR–MYC lineage plasticity) and BRAF-mutated AML prognosis. Parallel work emphasizes how biomarkers and patient selection are increasingly grounded in multi-omic and spatial/AI-derived features (e.g., Trop2 ADC eligibility via epigenetic regulation, NSCLC PET/CT deep-learning grading, and virtual spatial profiling from H&E), aiming to improve response prediction and treatment durability.

A second major theme is immune regulation across diseases, from cancer to autoimmunity and neurodegeneration. Tumor immune microenvironment studies highlight actionable axes such as PID1–cholesterol/oxysterol signaling in tumor-associated macrophages and a type II interferon–neutrophil–PD-L1 pathway affecting immunotherapy responses. In autoimmune disease, single-cell and mechanistic work in RA, Crohn’s, autoimmune hepatitis, and systemic sclerosis converge on immune-metabolic and regulatory-cell dysfunction (e.g., cortisol–AREG Treg dysregulation, microbial metabolite–driven hepatic immunosuppression, and RAC1-driven pericyte dysfunction). In neurodegeneration, human tissue and biomarker frameworks (including ARIA risk modeling for anti-amyloid therapy) continue to refine how interventions map onto brain pathology and safety.

Finally, several articles strengthen the “translation layer” of healthcare: living guidelines and systematic reviews (obesity pharmacotherapy, cardiovascular trial endpoints, resistant hypertension strategies, and intubation induction agents), plus pragmatic and real-world trials (e.g., perioperative/critical care interventions, biologic sequencing in Crohn’s, and complement inhibition in complement-driven glomerular disease). Together, these studies underscore a shift toward harmonized endpoints, standardized workflows (such as organoid quality control), and scalable risk tools—so that emerging therapies can be deployed more safely, effectively, and efficiently.

---

Targeted oncology (EGFR/KRAS/BRAF and precision therapy)

The KRAS G12D Inhibitor Pipeline Grows.

This article summarized emerging early clinical data for KRAS G12D–selective inhibitors, highlighting agents such as RNK08594, GFH375, and DN022150 presented at ASCO. The key finding is that multiple KRASG12D-targeted drugs show encouraging early activity across solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer. Scientifically and clinically, the growing pipeline supports KRASG12D as a tractable precision oncology target and motivates further trials to define efficacy and optimal combinations.

Cancer discovery · (2026) · View on PubMed ↗

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.

This phase 3, open-label, multicentre randomized controlled trial evaluated first-line aumolertinib with or without platinum-based chemotherapy versus aumolertinib monotherapy in patients with locally advanced or metastatic EGFR-mutated advanced non-small-cell lung cancer (NSCLC). The key finding was the comparative efficacy and adverse-event profile of adding platinum chemotherapy to aumolertinib versus using aumolertinib alone as initial therapy for EGFR-sensitive mutations. The results are clinically significant because they inform optimal first-line treatment selection to improve outcomes while managing toxicity in EGFR-mutated advanced NSCLC.

Li Z, Hu J, Chen J et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.

This study evaluated in patients with unresectable stage III EGFR-mutated non-small cell lung cancer the safety of osimertinib given after definitive chemoradiotherapy (CRT) in the phase III LAURA trial. Osimertinib showed a generally tolerable safety profile compared with placebo among patients randomized 2:1 who had not progressed during or after CRT. These safety findings support the clinical use of osimertinib as consolidation therapy after definitive CRT to improve outcomes while maintaining manageable toxicity in this molecularly defined population.

Kato T, Dong X, Takahashi T et al. · Lung cancer (Amsterdam, Netherlands) · (2026) · View on PubMed ↗

---

Immuno-oncology and tumor immune microenvironment

Targeting PID1 generates oxysterols to switch macrophage cell fates for improved antitumor immunity.

In tumor-associated macrophages (TAMs) across human pan-cancers, this study examined how targeting phosphotyrosine interaction domain-containing protein 1 (PID1) alters cholesterol metabolism to reprogram macrophage fate for antitumor immunity. PID1 deficiency in myeloid cells increased LDL receptor expression, enhanced LDL uptake, elevated intracellular free cholesterol and reactive oxygen species (ROS), and promoted cholesterol oxidation to generate oxysterols (including 5α,6α-epoxycholesterol and 7β-hydroxycholesterol) that switch macrophage cell fates. This is significant because it identifies PID1–oxysterol signaling as a mechanistic lever to improve antitumor immune responses.

Zheng Y, Wang Q, Dong C et al. · Nature cancer · (2026) · View on PubMed ↗

Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.

The study examined how oncogenic KRAS in pancreatic ductal adenocarcinoma (PDAC) activates innate immune signaling and affects cell death susceptibility, using genetically engineered mouse models with cancer-cell-specific gene deletions. It found that KRAS activates the cGAS–STING–TBK1 axis to induce type I interferon signaling that primes PDAC cells for necroptosis, with caspase-8 deletion triggering necroptotic death and reducing pancreatic precursor lesions. This links KRAS-driven interferon-stimulated gene programs (including MLKL via ISGF3) to a potentially targetable vulnerability to necroptosis in PDAC.

Tishina S, Dahlhaus A, Manik M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.

This study analyzed 1296 hepatocellular carcinoma (HCC) patients treated with frontline atezolizumab plus bevacizumab (A+B) and validated results in 645 IMbrave150/GO30140 trial participants to define a myeloid immunosuppressive phenotype associated with primary refractoriness (PRef). Using multi-parametric pre-treatment tumor profiling including machine learning-based quantification of tumor-infiltrating lymphocytes and imaging mass cytometry (IMC), the authors linked the phenotype to early progression or short-lived stabilization per SITC criteria. Scientifically and clinically, the work proposes a tissue-based biomarker strategy to predict which patients are unlikely to benefit from A+B and could guide alternative first-line approaches.

Lombardi P, Ramon-Gil E, Raja RQ et al. · Journal of hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.

This report provides 5-year outcomes from the phase 3 EMPOWER-Lung 3 Part 2 trial in 466 patients with previously untreated advanced non–small cell lung cancer (NSCLC) lacking EGFR, ALK, and ROS1 aberrations. Patients randomized 2:1 to cemiplimab (350 mg every 3 weeks up to 108 weeks) plus chemotherapy versus placebo plus chemotherapy showed sustained overall survival benefit, with progression-free survival and objective response rate as key secondary endpoints. Long-term results strengthen the evidence for adding the PD-1 inhibitor cemiplimab to chemotherapy as a durable first-line option in this biomarker-negative advanced NSCLC population.

Baramidze A, Makharadze T, Gogishvili M et al. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · (2026) · View on PubMed ↗

Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon.

This study examined how neutrophils regulate cancer immunotherapy and tested the role of type II interferon in controlling this effect using neutropenic mice and genetic perturbations. It found that neutrophils upregulated PD-L1 in response to IFN-γ produced by cytotoxic lymphocytes, and that genetic deletion of cd274 (PD-L1) or Ifngr1 (IFN-γ receptor) on neutrophils altered the immunotherapy response. The findings are significant because they identify a type II interferon–neutrophil–PD-L1 axis that can be therapeutically targeted to improve immunotherapy efficacy.

Pei S, Pan Y, Liang H et al. · Immunity · (2026) · View on PubMed ↗ · Free PDF ↗

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

This study analyzed longitudinal cerebrospinal fluid (CSF) and tumor samples from responders and non-responders after intracerebroventricular bivalent CAR T cell therapy in recurrent glioblastoma (GBM). It found that the endogenous immune compartment after CAR T infusion critically shaped post-infusion immune dynamics and was associated with response versus relapse. The significance is that it identifies immune-context determinants of CAR T effectiveness in recurrent GBM, informing strategies to improve durability of response.

Freeburg NF, Chafamo D, Konanur Gopikrishna G et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

---

Hematologic malignancies and targeted antibodies/ADCs

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

This analysis evaluated efficacy and safety of the fixed-duration outpatient regimen of subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) in the Japan subgroup of the phase III SUNMO trial for relapsed/refractory large B-cell lymphoma. Patients randomized to Mosun-Pola had superior outcomes versus rituximab plus gemcitabine-oxaliplatin (R-GemOx) with a manageable safety profile in the Japanese population. The findings support Mosun-Pola as an effective, practical treatment option for R/R LBCL in Japan.

Maruyama D, Goto H, Kumode T et al. · International journal of clinical oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

This multicentre, single-arm phase 1–2 trial (ITCC-059) studied single-agent inotuzumab ozogamicin in paediatric patients with very high-risk first B-cell acute lymphoblastic leukaemia relapse, including dose-finding for recommended use as monotherapy or with chemotherapy. The key finding was the preliminary antileukaemic activity and safety profile of inotuzumab ozogamicin in this high-risk paediatric relapse setting. Clinically, these data support development of targeted CD22-directed therapy to improve outcomes where conventional chemotherapy yields poor survival.

Peccatori N, Locatelli F, Ammerlaan ACJ et al. · The Lancet. Haematology · (2026) · View on PubMed ↗

---

Cancer biomarkers, prognostic models, and risk stratification

A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.

This study developed and validated a preoperative, interpretable machine learning model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients using real-world clinical data. Using random survival forests combined with white-box modeling, the authors built a survival tree based on exactly eight preoperative features (including tumor size and lymph node involvement) and validated it in an external cohort. The clinical significance is that it enables more precise, pre-surgery risk stratification for nonmetastatic renal cell carcinoma with transparent feature-based reasoning.

Larcher A, Traverso A, Scuri P et al. · Nature communications · (2026) · View on PubMed ↗

Evidence supporting the role of GIGYF2 in synapse development and autism.

This study analyzed the clinical and molecular features of acute myeloid leukemia (AML) patients with BRAF mutations among 5779 consecutively annotated cases treated at two major US cancer centers. Canonical and non-canonical BRAF mutations occurred in ~1% of patients and were associated with poor outcomes across newly diagnosed and relapsed/refractory disease settings. The results support BRAF mutation status as a prognostic biomarker and motivate further therapeutic stratification and targeted trials in BRAF-mutated AML.

Yu B, Zhu S, Xiao L et al. · Molecular psychiatry · (2026) · View on PubMed ↗

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

This study performed pan-cancer multi-omic integration to determine determinants of TACSTD2 (Trop2) expression relevant to Trop2-directed antibody-drug conjugate (ADC) therapy. Across >20,000 samples from TCGA, GTEx, and public atlases, TACSTD2 expression was restricted to epithelial lineages, enriched in multiple tumors, and showed consistent inverse association with DNA methylation, while genomic alterations were uncommon. These results indicate epigenetic regulation as a major driver of Trop2 levels and provide translational guidance for selecting patients likely to benefit from Trop2 ADCs.

Notini G, Galbardi B, Viale G et al. · NPJ precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Multimodal multitask deep learning for grading management system in non-small cell lung cancer.

This study developed and validated a multimodal multitask deep learning grading management system (MM-DLS) for non-small cell lung cancer (NSCLC) using pretreatment PET/CT images plus clinical variables. In 4,164 multi-center patients, MM-DLS simultaneously predicted NSCLC histologic subtype, TNM stage, and survival risk with strong discrimination in internal and external validation cohorts. The approach could improve non-invasive, standardized risk stratification and reduce diagnostic uncertainty in routine NSCLC management.

Liu X, Dai F, Dai J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study.

This multicenter retrospective real-world study evaluated whether EVITA (EV-ineligible criteria) predicts severe adverse events (grade ≥3 AEs) and early enfortumab vedotin (EV) discontinuation in patients with locally advanced or metastatic urothelial carcinoma treated with EV-based therapy. It compared 289 patients receiving first-line EV plus pembrolizumab (EVP) versus subsequent EV monotherapy and assessed EVITA categories (0, 1, ≥2) at baseline for associations with grade ≥3 AEs and discontinuation within 3 months. The clinical significance is that it tests whether baseline EVITA risk stratifies patients for toxicity and treatment persistence in routine practice.

Ishimoto K, Narita T, Sekine Y et al. · Urologic oncology · (2026) · View on PubMed ↗

---

Cancer genomics, epigenetics, and 3D genome regulation

Standard: human breast cancer organoids derived from diverse clinical sample sources.

The study developed a consensus-oriented standard for establishing, characterizing, quality controlling, and applying human breast cancer patient-derived organoids (PDOs) generated from diverse clinical sample sources (e.g., surgical tissues). The key finding is a standardized workflow intended to improve reproducibility across laboratories while preserving the histopathological, genetic, and functional features of parental breast tumors. This standardization supports more reliable translational research and precision oncology using breast cancer organoids derived from heterogeneous patient material.

Chen Z, Xu N, Chen M et al. · Cell regeneration (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Decoding common and rare noncoding variant effects across cellular and developmental contexts.

The study used deep learning sequence models of chromatin accessibility to interpret effects of common and ultra-rare noncoding variants across diverse fetal and adult cellular contexts, generating ~3 billion predictions. The key finding is a variant-effect dichotomy: common variants show more cell-type-specific effects, whereas ultra-rare variants have larger and broader effects across cell types with strongest evidence of purifying selection in fetal neurons, leading to the development of FLARE (Functional Lasso Analysis of Regulatory Evolution). This advances noncoding variant prioritization for functional follow-up and improves interpretation of regulatory variants in human development.

Marderstein AR, Kundu S, Padhi EM et al. · Nature genetics · (2026) · View on PubMed ↗

3D multi-omics tumour atlases: from technology to biology and clinical translation.

This review discusses the development of 3D multi-omics tumour atlases, covering technologies, biological insights, and clinical translation for understanding tumor evolution in space and time. The key finding is that spatial multi-omics and 3D atlas approaches are increasingly enabling characterization of interacting cell ecosystems across pre-malignant lesions, tumor initiation, progression, invasion, and metastasis. Clinically, these atlases are positioned to improve early interception and treatment by capturing tumor microenvironment dynamics beyond 2D or single-modality views.

Liu M, Villazon J, Forjaz A et al. · Nature reviews. Cancer · (2026) · View on PubMed ↗

A generalizable Hi-C foundation model for chromatin architecture, single-cell and multiomics analysis across species.

This work developed HiCFoundation, a foundation model trained on large-scale Hi-C data to integrate 3D chromatin architecture with epigenomic assays such as ATAC-seq and ChIP-seq across species, including single-cell and multiomics contexts. The model enables generalizable integrative analysis that links chromatin structure to downstream regulatory function despite differences in Hi-C data formats, resolution, and analytical pipelines. Scientifically, it provides a scalable computational framework for interpreting how 3D genome organization regulates gene regulation across cell types and organisms.

Wang X, Zhang Y, Ray S et al. · Nature methods · (2026) · View on PubMed ↗

---

Cancer cell biology and therapeutic vulnerabilities

Nano-enabled spatially selective protein degradation modulates lactate metabolism to potentiate antitumor immunity in liver cancer.

The study engineered polymer-based lysosome-targeting chimeras to selectively degrade CD147 (a chaperone co-expressed with MCT1 and MCT4) in liver cancer cells to modulate lactate metabolism and enhance antitumor immunity. The key finding is that CD147 degradation reduces lactate efflux, reprograms tumor lactate metabolism within the tumor microenvironment, and potentiates antitumor immune responses while aiming to avoid systemic toxicity associated with MCT inhibitors. This provides a targeted protein-degradation strategy to therapeutically reshape cancer metabolism and improve immunotherapy efficacy in liver cancer.

Du J, Han S, Song R et al. · Nature nanotechnology · (2026) · View on PubMed ↗

Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.

This study investigated WFS1 as a vulnerability in KRASG12D-driven pancreatic ductal adenocarcinoma (PDAC), including mechanisms of adaptive resistance to the KRASG12D inhibitor MRTX1133. WFS1 expression increased after KRASG12D activation and was further elevated in tumors resistant to MRTX1133, and targeting WFS1 overcame KRASG12D dependency and reduced adaptive resistance. Clinically, it identifies WFS1 as a potential therapeutic target to improve durability of KRASG12D inhibitor treatment in PDAC.

Chen Y, Zhang J, Miao Y et al. · NPJ precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolution.

Using mouse models of lung adenocarcinoma, this study examined how activation of the integrated stress response (ISR), marked by phosphorylated eIF2 (p-eIF2) and ATF4 induction, drives tumor lineage reprogramming and heterogeneity. ISR activation promoted emergence of high-plasticity, undifferentiated pre-epithelial-to-mesenchymal transition clusters with elevated ATF4 and MYC activity in a MYC-dependent manner. These results connect mitochondrial/ISR signaling to cancer evolution and therapy resistance, highlighting ISR–MYC axis as a potential intervention point.

Diao S, Zou JY, Wang S et al. · Nature cell biology · (2026) · View on PubMed ↗ · Free PDF ↗

Cathepsin L deletion enhances sensitivity to anticancer drugs through Parkin-mediated ubiquitination of Bcl-xL and USP53-induced Survivin destabilization.

This study tested whether deletion of cathepsin L (Cathepsin L/Cat L) sensitizes renal clear carcinoma cells to anticancer drugs by modulating apoptosis regulators, focusing on Parkin-mediated ubiquitination of Bcl-xL and USP53-induced Survivin destabilization. Cat L inhibition/knockdown/knockout downregulated Bcl-xL and Survivin at the post-translational level, increased drug-induced apoptosis, and combined Cat L inhibition with sorafenib reduced tumor growth in xenografts. Mechanistically, Cat L deletion stabilized Parkin via increased DUB3 expression, suggesting a pathway that could be therapeutically exploited to enhance anticancer efficacy.

Seo SU, Woo SM, Kwon Y et al. · Cell death and differentiation · (2026) · View on PubMed ↗ · Free PDF ↗

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.

This study investigated how loss of the chromatin remodeler SMARCA4 (BRG1) reprograms transcriptional repression in ovarian small cell carcinoma, a cancer driven by biallelic SMARCA4 inactivation while retaining wild-type p53. SMARCA4 loss redistributed the p300 acetyltransferase to promoters of cell-cycle genes, increased H3K27 acetylation, and promoted transcription that counteracted p53-mediated transcriptional repression. The work links SMARCA4 deficiency to a p300/H3K27ac-driven escape from p53 control, suggesting chromatin co-regulation as a therapeutic vulnerability in SCCOHT.

Aceto G, Liu K, Arabzadeh A et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Systematic discovery of UFM1 receptors reveals a regulatory module in DNA repair directing non-homologous end-joining.

This study systematically discovered UFM1 receptors and defined a regulatory module for DNA repair by focusing on UFM1’s role in non-homologous end-joining (NHEJ). Using structure-guided chemical biology, including a photo-crosslinkable UFM1 probe plus NMR, it mapped UFM1-binding interfaces in core NHEJ factors and, via proximity-dependent proteomics and functional assays, identified Ku70 as a crucial UFMylation substrate within an XRCC4–UFMylated Ku70 axis. These findings mechanistically connect UFM1 signaling to NHEJ pathway control, expanding the UBL-based framework for genome maintenance and DNA damage response regulation.

Wang Z, Foster BM, da Costa IC et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.

The study examined how CD147-positive migrasomes (large extracellular vesicles) drive hepatocellular carcinoma (HCC) resistance to sorafenib by promoting vasculogenic mimicry, focusing on signaling through PI3K/AKT/TWIST1. It found that hypoxia increases migrasome release and CD147 expression on migrasomes, and that this promotes vasculogenic mimicry and sorafenib resistance via PI3K/AKT/TWIST1 signaling. This identifies the CD147+ migrasome–PI3K/AKT/TWIST1 pathway as a potential target to overcome sorafenib resistance in HCC.

Qian L, Chen P, Wang B et al. · Cell death & disease · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardio-oncology and cardiovascular safety endpoints

TFEB Antagonizes Cardiac Hypertrophy and Failure by Enhancing Lysosomal Capacity and Mitochondrial Function.

This study examined whether antagonizing TFEB (transcription factor EB) in cardiomyocytes affects pressure-overload cardiac hypertrophy and heart failure in a cardiomyocyte-specific TFEB knockout mouse model. TFEB loss reduced lysosomal capacity and impaired mitochondrial function, worsening hypertrophy and failure, whereas enhancing lysosomal/mitochondrial pathways mediated the protective effects. These findings position TFEB-lysosome/mitochondria signaling as a potential therapeutic target to limit pathological remodeling and improve outcomes in heart failure.

Daou D, Das Gupta S, Anand A et al. · Circulation research · (2026) · View on PubMed ↗

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

This American Heart Association scientific statement reviewed how to define and measure cardiovascular endpoints in oncology clinical trials to better detect and characterize treatment-related cardiotoxicity. It highlighted that inconsistent endpoint definitions and variable event characterization have limited progress, and it outlined challenges and opportunities for standardizing cardiovascular safety assessment across trials. This is scientifically significant because improved endpoint harmonization can enable earlier, more reliable detection of vascular, myocardial, and metabolic toxicities and thereby improve patient safety in cancer therapy development.

Barac A, Guha A, Fleming TR et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

---

Cardiovascular disease and interventional cardiology outcomes

10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis.

This study analyzed 10-year outcomes from the PARTNER 2A randomized trial in intermediate-risk patients with severe, symptomatic aortic stenosis comparing transcatheter aortic valve replacement (TAVR) using the balloon-expandable SAPIEN XT system versus surgical aortic valve replacement. The key finding was that long-term clinical and echocardiographic outcomes differed between TAVR and surgery over a decade. This is significant for long-term decision-making in intermediate-risk patients by providing durable comparative effectiveness and valve performance data.

Thourani VH, von Stein P, Mack MJ et al. · Journal of the American College of Cardiology · (2026) · 4 citations · View on PubMed ↗ · Free PDF ↗

---

Neuroscience, neurodegeneration, and brain circuitry

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease.

This neuropathological study assessed postmortem brain tissue from six participants in aducanumab (anti–Aβ) clinical trials and compared it with nine untreated Alzheimer’s disease (AD) patients matched for age, APOE genotype, and Braak neurofibrillary tangle stage. The key finding was that aducanumab exposure altered brain Aβ pathology and related AD phenotypes relative to matched untreated controls. Clinically, it provides direct human tissue evidence for how aducanumab’s anti-amyloid immunotherapy impacts AD neuropathology beyond fluid/imaging biomarkers.

Welikovitch LA, Oakley DH, Bennett RE et al. · Acta neuropathologica · (2026) · View on PubMed ↗

Integrating Single-Cell Transcriptomics and Mendelian Randomization to Identify RAC1 as a Causal Metabolic Driver of Pericyte Dysfunction in Systemic Sclerosis.

This study integrated single-cell RNA sequencing (scRNA-seq) from systemic sclerosis (SSc) patients with genome-wide association study (GWAS) data using bidirectional Mendelian randomization to identify causal drivers of pericyte dysfunction. The key finding was that RAC1 emerged as a causal metabolic driver of pericyte dysfunction, supported by the combined single-cell and genetic evidence. This is significant because it prioritizes RAC1 as a mechanistic target for preventing pericyte-to-pathological transition and subsequent fibrosis in systemic sclerosis.

Wang X, Zhang Z, Jiang E et al. · Mediators of inflammation · (2026) · View on PubMed ↗ · Free PDF ↗

Sleep and dementia: Assessing established dementia-related factors using multivariable Mendelian randomization.

This study used two-sample and multivariable Mendelian randomization to assess whether sleep traits and established dementia risk factors causally relate to dementia outcomes, including Alzheimer’s disease (AD). Using genetic instruments from UK Biobank for sleep and summary statistics from FinnGen for dementia, the key finding was that specific sleep characteristics show causal associations with dementia risk, and multivariable MR helped determine whether these effects persist after accounting for other dementia-relevant factors. Scientifically, it strengthens causal inference beyond observational studies and may guide prevention strategies targeting modifiable sleep features.

Guo Y, Wang R, Sindi S et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

The impact of cognitive behavioral therapy for insomnia on cognitive performance and amyloid beta in older adults: A randomized controlled trial.

This randomized controlled trial tested whether cognitive behavioral therapy for insomnia (CBT-I) improves cognitive performance and reduces amyloid beta (Aβ) burden in cognitively normal older adults. In 100 participants assigned to CBT-I and 100 to control (with Aβ measured in a subsample of 50), the key finding was no significant difference between groups in change in cognitive performance and no clear CBT-I effect on Aβ burden based on the reported results. Clinically, it suggests CBT-I may not directly alter AD biomarkers or cognitive trajectories over the study timeframe, highlighting the need for longer follow-up or targeted biomarker subgroups.

Siengsukon CF, Hand LK, Nelson E et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Biomarker Based ARIA Stress Test: A Proposed Conceptual Framework for Dynamic Biomarker-Guided ARIA Risk Stratification in Anti-Amyloid Immunotherapy for Alzheimer’s Disease.

This paper proposes a conceptual, biomarker-based ARIA stress test framework for dynamic ARIA risk stratification in anti-amyloid immunotherapy for Alzheimer’s disease, synthesizing published evidence on ARIA pathophysiology and plasma biomarkers. The key finding is a kinetic (velocity-driven) model linking ARIA risk to dynamic biomarker behavior using markers including GFAP, the Aβ42/40 ratio, NfL, and p-tau217. Clinically, the framework aims to enable more responsive, biomarker-guided safety risk management for anti-amyloid therapies, though it is not yet validated with empirical trial data.

Fang S, Chen S · Journal of molecular neuroscience : MN · (2026) · View on PubMed ↗

Mechanisms of increased Alzheimer’s disease pathology with R47H and R62H TREM2 variants.

This study compared human post-mortem brain pathology in individuals with and without Alzheimer’s disease to test how TREM2 variants R47H and R62H (TREM2var) interact with the protective CD33 rs3865444 allele. Carriers of TREM2var showed increased β-amyloid load differences that were partially normalized by heterozygosity for the protective CD33 allele, demonstrating CD33–TREM2 epistasis. These findings clarify a genetic mechanism linking microglial TREM2 and CD33 pathways to Alzheimer’s disease progression and suggest CD33-modulating biology may mitigate TREM2-driven pathology.

Fancy NN, Willumsen N, Chau VMN et al. · Acta neuropathologica · (2026) · View on PubMed ↗ · Free PDF ↗

Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial.

In a randomized crossover feasibility trial in five patients with Parkinson’s disease, this study evaluated gait-synchronized adaptive deep brain stimulation (aDBS) that modulates stimulation based on gait phase versus continuous DBS. Gait-synchronized aDBS was feasible and safe and reduced falls compared with continuous stimulation. This provides early clinical evidence that temporally precise, behavior-contingent DBS can better address dynamic gait dysfunction in Parkinson’s disease.

Louie KH, Balakid JP, Bath JE et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Redefining hypersomnia disorders in the context of psychiatry.

This psychiatry-focused review re-examines how to define and attribute daytime sleepiness and excessive sleep, emphasizing differential diagnosis among depression, insufficient sleep, shift work, and obstructive sleep apnea (OSA) in the general population. It argues that because mild OSA often contributes modestly to sleepiness and stimulants have limited evidence when used as adjuncts in depression, current approaches may over-treat OSA and misattribute symptoms. Clinically, the article supports more precise diagnostic pathways to reduce unnecessary treatment and better target underlying causes of hypersomnia symptoms.

Mignot E · L’Encephale · (2026) · View on PubMed ↗ · Free PDF ↗

Rapid strengthening and reversal of hippocampal-neocortical interplay mediates human memory formation.

This human electrophysiology study used day-by-day multisite intracranial recordings in subjects performing a repeated picture-learning task to examine hippocampal–neocortical dynamics during memory formation. It found that ripple rates in both hippocampus and neocortex increased from day 1 to day 2 during learning and free recall, and that hippocampal–neocortical ripple coupling strengthened from day 2 onward in relation to behavioral memory performance. The clinical/scientific significance is that it provides direct temporal evidence for how hippocampal–neocortical interaction evolves across days to support human memory consolidation.

Wang L, Duan Q, Song J et al. · Neuron · (2026) · View on PubMed ↗

Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay : A Target Trial Emulation.

This target trial emulation cohort study estimated in older adults with a recent skilled-nursing facility (SNF) stay the association between recombinant herpes zoster vaccine (RZV) receipt within 12 months of SNF entry (or after discharge) and subsequent dementia risk. The key finding was not present in the truncated abstract text provided. Establishing whether RZV is associated with lower dementia incidence in this high-risk population would be clinically significant for vaccination policy and dementia prevention strategies.

Hayes KN, Harris DA, McConeghy KW et al. · Annals of internal medicine · (2026) · View on PubMed ↗

---

Infectious disease and host-pathogen interactions

A CRISPR knockout mouse library for functional genomics in influenza research.

This study created a CRISPR-Cas9 knockout mouse library for functional genomics in influenza A virus research by generating 84 gene-modified mouse lines targeting prioritized host factors. In vivo screening identified 17 host factors whose genetic ablation conferred resistance to influenza A infection, with follow-up analyses performed for two factors. The scientific significance is that it provides a systematic whole-animal platform to validate host determinants of influenza pathogenesis beyond in vitro findings.

Ueki H, Tomita Y, Duong C et al. · Cell · (2026) · View on PubMed ↗

Overcoming methicillin resistance in Staphylococcus aureus via metal ion disruption of bacterial metabolism.

This study investigated how the synthetic ionophore PBT2, delivering zinc (Zn) into the cytosol, disrupts metal ion homeostasis to overcome methicillin resistance in Staphylococcus aureus (MRSA). The key finding is that PBT2/Zn (PZ) induces metal-dependent vulnerabilities by dysregulating bacterial processes and restoring susceptibility to conventional antibiotics. Scientifically, it supports a host-inspired strategy of targeting bacterial metal metabolism as an alternative to traditional antibiotic mechanisms.

Macbeth EK, Todd Rose F, Cheung CY et al. · npj antimicrobials and resistance · (2026) · View on PubMed ↗ · Free PDF ↗

WHO estimates of the global, regional, and national burden of 14 foodborne diarrhoeal enteric hazards, 2000-21: an updated data synthesis.

This study updated WHO estimates of global, regional, and national illness, death, and disability-adjusted life-years (DALYs) from 14 foodborne diarrhoeal enteric hazards across 194 countries from 2000–2021. It found substantial, persistent burdens attributable to multiple pathogens including Campylobacter spp, norovirus, rotavirus, non-typhoidal Salmonella, Shiga toxin–producing E. coli, Shigella spp, and Vibrio cholerae, with estimates synthesized from available surveillance and modeling data. These updated burden estimates are important for prioritizing food-safety interventions and targeting prevention and control strategies by country and pathogen.

Majowicz SE, Colston JM, Kirk MD et al. · The Lancet. Global health · (2026) · View on PubMed ↗ · Free PDF ↗

---

Vaccines and immunology (including B-cell responses)

mRNA-based influenza vaccine expands the B cell response breadth in humans.

This observational human study assessed B cell responses in healthy young adults receiving either a licensed split-virion influenza vaccine or an investigative mRNA-based quadrivalent seasonal influenza vaccine over two consecutive seasons. mRNA vaccination produced higher antibody titers and increased memory B cell frequencies and induced sustained germinal center reactions in draining lymph nodes in a subset of participants. Immunologically, it shows that mRNA influenza vaccines can broaden and strengthen the B cell response, supporting their potential for improved protection against antigenically diverse influenza strains.

Matz HC, Yu TG, Dixit K et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

A temporal map of B cell diversification mechanisms in mice.

This study mapped temporal mechanisms of B cell diversification in mice during Plasmodium infection, tracking how individual clones change over time. Early after infection, isotype switching begins soon after Myc upregulation and overlaps with clonal expansion (isotype variegation), while later expanded clones seed germinal centers, bifurcate into extrafollicular plasmablasts, and initiate somatic hypermutation. These findings define a time-resolved model of how clonal expansion, isotype switching, and SHM are coordinated to generate antibody diversity during malaria.

Skinner OP, Asad S, Moreira ML et al. · Nature immunology · (2026) · View on PubMed ↗

---

Autoimmune disease (RA, Crohn’s, AIH, SSc, IBD genetics)

Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases.

Using single-cell RNA sequencing of synovial tissue from patients with rheumatoid arthritis (RA), this study characterized functional and dysfunctional FOXP3+ regulatory T (Treg) cell states in RA and other autoimmune arthritic diseases. It identified two predominant tissue-enriched Treg states—CD25hiCXCR6pos Treg cells and dysfunctional CD25loAREGpos Treg cells—where fibroblast-activated cortisol drives AREG expression, impairs suppressive function, and AREG promotes an inflammatory phenotype in synovial fibroblasts. These findings are significant because they define a cortisol–AREG axis that may be targeted to restore Treg-mediated immune control in RA.

Koh B, Gal Oz ST, Sato R et al. · Nature immunology · (2026) · View on PubMed ↗

The bacteroidal metabolite O-LysoPE facilitates hepatocyte-mediated immunosuppression in autoimmune hepatitis.

This study investigated how the gut microbiota metabolite O-LysoPE affects immune regulation in autoimmune hepatitis (AIH), comparing self-healing mouse hepatitis models and human AIH patients. It found that Bacteroides acidifaciens and its metabolite 1-oleoyl-sn-glycero-3-phosphoethanolamine (O-LysoPE) are enriched in self-healing models but depleted in AIH patients, and that O-LysoPE induces hepatocyte-driven active immunosuppression. The work is significant because it links a specific microbial metabolite to hepatic immune homeostasis and suggests a more targeted alternative to broad systemic immunosuppression.

Xu M, Luo K, Zhou Z et al. · Nature communications · (2026) · View on PubMed ↗

Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn’s Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany.

This pooled real-world analysis used individual patient data from the prospective UMBRELLA-IBD registry in Germany to compare anti-TNF therapy (adalimumab or infliximab) versus ustekinumab and vedolizumab in 1,567 adults with Crohn’s disease over 24 months. Using propensity-score-based inverse probability of treatment weighting, the key finding was the comparative effectiveness in achieving clinical remission (HBI ≤4) at 24 months and differences in treatment persistence across biologics. Clinically, it helps clinicians choose among biologics based on expected remission and durability in routine care.

Bokemeyer A, Tran F, Plachta-Danielzik S et al. · Alimentary pharmacology & therapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.

This review summarizes current and emerging diagnostic, prognostic, and therapeutic biomarkers in rheumatoid arthritis (RA) across genetic, protein, imaging, and multi-omics domains. The key finding is that robust biomarker tools are still insufficient for timely diagnosis, accurate risk stratification, and optimal treatment selection, despite rapid advances in biomarker discovery. Clinically, improving biomarker-driven decision making is positioned to increase the proportion of patients achieving sustained remission and to better manage comorbidities.

Szekanecz Z, Gunkl-Tóth L, Szamosi S et al. · Nature reviews. Rheumatology · (2026) · View on PubMed ↗

Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn’s disease pathogenesis.

The study performed single-cell RNA sequencing (scRNA-seq) on terminal ileal biopsies to identify molecular signatures of Crohn’s disease pathogenesis using the IBDverse dataset comprising 1.1 million cells from 111 Crohn’s patients and 232 healthy controls. The key finding is identification of Crohn’s-associated cell types and pathways, including epithelial interferon-driven upregulation of major histocompatibility complex class I molecules that persists in progenitor cells after macroscopic inflammation. This provides a high-resolution cellular map of disease mechanisms that can guide biomarker discovery and therapeutic targeting in Crohn’s disease.

Krzak M, Alegbe T, Taylor DL et al. · Nature genetics · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Pyoderma gangrenosum caused by the molecular uncoupling of OTULIN catalytic activity and LUBAC binding.

This study investigated pyoderma gangrenosum (PG) in three pediatric patients from two unrelated kindreds carrying a homozygous R57C mutation in the linear deubiquitinase OTULIN. OTULIN-R57C remained catalytically active but uncoupled OTULIN catalytic activity from binding to the linear ubiquitin assembly complex (LUBAC), leading to heightened IL1B expression in patient monocytes and failure to suppress downstream inflammatory signaling. These findings define a distinct OTULIN-related PG (ORP) mechanism driven by disrupted OTULIN–LUBAC interaction rather than loss of catalytic activity, informing more precise molecular diagnosis and pathway-targeted therapy.

Swaminathan B, Gil HM, Bhattad S et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Real-World Outcomes of Upadacitinib Versus Risankizumab Among Anti-TNF Exposed Patients with Crohn’s Disease.

In a retrospective single-center cohort of adults with active luminal Crohn’s disease previously exposed to anti-TNF inhibitors, the study compared upadacitinib (UPA) versus risankizumab (RSZ) initiated between January 2022 and November 2025. The primary outcome was corticosteroid-free (CSF) clinical remission during post-induction weeks 12–24, with additional CSF remission and combined clinical/biochemical remission assessed through week 52. The findings aim to inform real-world sequencing after anti-TNF failure by identifying which mechanism (JAK inhibition vs IL-23 blockade) yields better steroid-sparing remission.

McShane C, Olivera PA, Candido K et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · (2026) · View on PubMed ↗

HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study.

This genotype–phenotype association study assessed whether HLA-DRB101:03 is associated with inflammatory bowel disease (IBD) subphenotypes and adverse outcomes beyond severe ulcerative colitis, using patients of inferred European ancestry recruited from more than 100 UK hospitals. The key finding was the extent to which HLA-DRB101:03 contributes to specific IBD subtypes and outcomes, including consideration of links to neutralising auto-antibodies against IL-10. This is scientifically significant because it refines genetic risk stratification for IBD heterogeneity and may clarify immunologic mechanisms underlying disease subphenotypes.

Zhang Q, Shakweh E, Sharip MT et al. · The lancet. Gastroenterology & hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Targeting barrier integrity: Pseudoginsenoside RT2 ameliorates ulcerative colitis by driving epithelial renewal via the Wnt/β-catenin pathway.

This preclinical study tested pseudoginsenoside RT2 for ulcerative colitis (UC) using LPS-stimulated Caco-2 epithelial cells and a DSS-induced mouse model, and used integrated transcriptomic and proteomic analyses to define mechanisms. It found that RT2 ameliorated UC and drove epithelial renewal by activating the Wnt/β-catenin pathway, supporting barrier restoration as a key mechanism. The scientific and translational significance is that RT2 emerges as a candidate barrier-protective therapy with a defined signaling pathway for UC treatment development.

Li Z, Tan L, Wu J et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

---

Renal and urologic medicine (including glomerular disease, C3G, BPO, intubation/airway)

GLUT9b- and ABCG2-mediated collecting duct urate transport uncover a vasopressin-independent mechanism of renal water reabsorption.

This mechanistic study investigated how collecting duct urate transport regulates renal water reabsorption independently of vasopressin in collecting duct cells and related models. It found that intracellular soluble urate—driven by increased apical uptake via GLUT9b and decreased apical efflux via ABCG2—activates PDE4, reduces cAMP, and triggers AMPK activation, leading to AQP2 accumulation and enhanced water reabsorption. These results identify a vasopressin-independent GLUT9b/ABCG2–urate–PDE4–AMPK pathway that could be targeted to modulate water balance disorders.

Hadla M, Mardirossian JM, Bichet DG et al. · The Journal of clinical investigation · (2026) · View on PubMed ↗ · Free PDF ↗

Clinical practice recommendations for the diagnosis and management of nephropathic cystinosis.

This article provides clinical practice recommendations for diagnosing and managing nephropathic cystinosis, a lysosomal storage disorder caused by pathogenic variants in CTNS (cystinosin). The key finding is an evidence-based care framework describing disease mechanisms (lysosomal cystine accumulation and crystal formation) and current management approaches including cysteamine therapy plus supportive renal replacement strategies. Scientifically and clinically, the recommendations help standardize treatment to slow progression from early renal Fanconi syndrome to chronic kidney disease and improve long-term outcomes into adulthood.

Hohenfellner K, Wühl E, Haffner D et al. · Nature reviews. Nephrology · (2026) · View on PubMed ↗ · Free PDF ↗

Real-world outcomes of pegcetacoplan treatment in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.

In a real-world observational cohort using the CompCure registry and an international survey, pediatric and adult patients with C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN), largely resistant to conventional immunosuppression, were treated with pegcetacoplan, a C3/C3b inhibitor. The study assessed changes in urine protein-to-creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), and serum C3 over 1, 3, 6, and 12 months. If confirmed, these effectiveness and safety data could support broader clinical use of complement inhibition for complement-driven glomerular diseases with limited response to standard therapy.

Bassanese G, Weingarten AM, Mancuso MC et al. · Kidney international · (2026) · View on PubMed ↗

---

Endocrinology, obesity, and metabolic health

Long-term ovarian function risks associated with combined oral contraceptive administration in polycystic ovary syndrome: multisource data integration and protective mechanisms of metformin.

This multisource integration study assessed long-term ovarian function decline risk associated with combined oral contraceptives (COCs) in women with polycystic ovary syndrome (PCOS) and evaluated metformin’s protective mechanisms. Using 336 PCOS patients plus disproportionality analysis of 3,424 COC-related ovarian-function adverse event reports from FAERS, the study found that COC exposure was associated with ovarian reserve/function decline signals and that metformin-related target/protective mechanisms may mitigate these risks. The work supports considering metformin as a potential risk-modifying strategy when COCs are used long term in PCOS.

Li J, Wei J, Liu C et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Head-to-head comparison of fasting-insulin-based versus non-insulin-based insulin resistance surrogates for predicting all-cause and cardiovascular mortality in hypertensive adults across the glycemic continuum: a prospective cohort study.

This prospective cohort study in hypertensive adults across the glycemic continuum compared fasting-insulin-based insulin resistance surrogates (HOMA-IR, McAuley index, QUICKI) versus non-insulin-based indices (including TyG, SHR, CMI, AIP, eGDR, METS-IR, and lipid-based measures) for predicting all-cause and cardiovascular mortality. The key finding was that insulin-resistance indices differed in their ability to predict mortality depending on whether they were insulin-based or non-insulin-based across glycemic strata. Scientifically, it clarifies which surrogate best captures risk in hypertension, and clinically it guides selection of practical IR measures for prognosis.

Abdu FA, Mohammed AQ, Zhang W et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

Adiposity and cancer: systematic review and meta-analysis.

This systematic review and meta-analysis studied prospective cohort evidence linking adiposity, measured by body mass index (BMI), to cancer incidence across 25 cancer types. Higher BMI was positively associated with risk of 19 cancers and inversely associated with 3, based on 226 studies comprising ~1.5 million incident cancers, with notable positive associations including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma. These findings strengthen the epidemiologic rationale for obesity-focused prevention and highlight cancer types where adiposity–risk relationships may be under-recognized.

Watts EL, Gonzalez-Feliciano A, Gunter MJ et al. · Nature metabolism · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Adiposity and cancer: epidemiology, mechanisms and future perspectives.

This Review synthesized evidence on how excess adiposity contributes to cancer risk and discussed future research directions for improving risk prediction and mechanistic understanding. It emphasizes key pathways including sex hormones, hyperinsulinaemia, and chronic inflammation, and highlights emerging insights from omics technologies and tumor subtype-specific associations. The review supports more precise, mechanism-informed prevention strategies and calls for improved adiposity measurement approaches (e.g., imaging-based measures) to refine causal inference.

Watts EL, Gonzalez-Feliciano A, Gunter MJ et al. · Nature metabolism · (2026) · View on PubMed ↗

Multi-omics reveals microbiota, metabolite, and immunological heterogeneity of age-related endotypes in type 1 diabetes.

The study used integrated multi-omics (microbiome, metabolome, lipidome, and transcriptome) to characterize age-related endotypes in 108 newly diagnosed pediatric patients with type 1 diabetes (T1D) versus 56 healthy controls. It identified distinct molecular signatures across early-onset (<7 years), intermediate-onset (7–12 years), and late-onset (≥13 years) T1D groups, including enriched microbial taxa such as Acetatifactor in early-onset disease. This stratification supports the concept of age-dependent immune-metabolic-microbiome subtypes that could guide more tailored mechanistic studies and future interventions.

Pan L, Tan H, Yue T et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.

The study analyzed real-world prescribing patterns of incretin-based therapies in women with polycystic ovary syndrome (PCOS) using electronic health records from a Polish private healthcare network (LUX MED). It found temporal trends in initiation of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide after PCOS diagnosis, based on a cohort of 38,263 adult women with ICD-coded PCOS. These findings provide population-level evidence on how incretin therapies are being adopted in PCOS care and can inform future guideline and outcomes research.

Dziewierz A, Kulicka N, Stolarska K et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Multidimensional effects of personalized exercise intervention in type 2 diabetes: a randomized controlled trial.

The study conducted a randomized controlled trial in adults with type 2 diabetes (T2D) and abdominal obesity to test whether a 16-week personalized exercise program improves fat mass and related metabolic and cognitive outcomes. It found that the personalized combined training (tailored aerobic capacity and muscle strength) produced multidimensional benefits compared with habitual lifestyle control, with fat mass as the primary endpoint. This supports personalized exercise as an effective nonpharmacologic strategy to address both metabolic and functional impairments in T2D.

Liu D, Cheng D, Wang Q et al. · Science bulletin · (2026) · View on PubMed ↗

SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.

SURMOUNT-REAL UK is a phase 4, pragmatic randomized clinical trial evaluating tirzepatide added to standard-of-care (SoC) in ~3000 UK adults with Class I obesity (BMI 30–34.9 kg/m2) without diabetes in Greater Manchester primary care. The primary endpoint is percent change in body weight from baseline to Month 24, comparing tirzepatide+SoC versus SoC alone. If effective in real-world practice, tirzepatide could expand evidence for scalable weight-loss pharmacotherapy in primary care for non-diabetic obesity.

Rutter MK, Mount J, Gibson JM et al. · Obesity (Silver Spring, Md.) · (2026) · View on PubMed ↗ · Free PDF ↗

High-intensity interval training and moderate-intensity continuous training are effective, feasible, and safe for patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.

This systematic review and meta-analysis synthesized controlled trials (37 trials; 1546 participants, 51% female) testing high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). HIIT significantly improved multiple outcomes compared with controls across 12 endpoints, and both HIIT and MICT were concluded to be effective, feasible, and safe, with moderators explored. The results support exercise prescription as an evidence-based adjunct strategy for MASLD management, potentially improving metabolic and liver-related health without major safety concerns.

Wang B, Zeng X, Deng H et al. · Metabolism: clinical and experimental · (2026) · View on PubMed ↗

Validated early detection metrics reduce the population requiring liver fibrosis screening.

Using NHANES 2017–2020 adults aged 18–80 years with BMI ≥18.5 kg/m2 and no excessive alcohol use, the study developed and validated refined early detection metrics for liver fibrosis screening based on stratified risk of liver stiffness measurement (LSM) ≥8 kPa. By targeting only subgroups with ≥10% prevalence of LSM ≥8 kPa risk, the refined criteria reduced the proportion of the general population requiring screening while maintaining linkage to liver-related events in four cohorts. This could improve the efficiency and cost-effectiveness of fibrosis screening programs by focusing resources on those most likely to have clinically relevant fibrosis.

van Kleef LA, Pustjens J, Schneider CV et al. · Gastroenterology · (2026) · View on PubMed ↗ · Free PDF ↗

Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.

This systematic review assessed, in U.S. adults with overweight or obesity, the cost-effectiveness of pharmacologic weight-management treatments using non-industry-sponsored trial-based and model-based economic evaluations. Across included studies, the review synthesized comparative economic outcomes (e.g., cost per health outcome) for multiple drug strategies in real-world-relevant U.S. settings. The findings are significant for informing U.S. payer and guideline decisions about which anti-obesity medications provide value for money alongside clinical benefits.

Jenniskens K, Huis In ‘t Veld LF, Lokerse ME et al. · Annals of internal medicine · (2026) · 3 citations · View on PubMed ↗

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

This living systematic review and network meta-analysis evaluated in U.S. adults with overweight or obesity the benefits and harms of pharmacologic weight-management treatments using randomized controlled trials through October 2025. It compared multiple agents—including GLP-1–based therapies (e.g., semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide), dual incretin strategies (e.g., tirzepatide), and other options such as naltrexone-bupropion and phentermine-based regimens—while synthesizing comparative efficacy and adverse effects. The results are clinically significant because they provide an up-to-date evidence map of which medications best balance weight-loss benefits against harms for shared decision-making.

Damen JAA, Idema DL, Vernooij RWM et al. · Annals of internal medicine · (2026) · 3 citations · View on PubMed ↗

Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).

This living clinical guideline synthesized evidence in nonpregnant outpatient adults with overweight or obesity on pharmacologic treatments used alongside lifestyle modifications. It used systematic reviews and the GRADE framework to issue conditional recommendations for initiating specific anti-obesity medications (with the abstract truncated before listing all agents). The guideline is significant because it translates comparative evidence on benefits and harms into practical, evidence-based prescribing recommendations for clinicians.

Qaseem A, Cross JT, Harrod CS et al. · Annals of internal medicine · (2026) · 3 citations · View on PubMed ↗

---

Clinical trials, guidelines, and perioperative/critical care interventions

On-Scene, Residential Extracorporeal Cardiopulmonary Resuscitation for Refractory Out-of-Hospital Cardiac Arrest: Operational and Logistical Considerations.

This report describes the first on-scene, residential extracorporeal cardiopulmonary resuscitation (ECPR) performed in North America for refractory out-of-hospital cardiac arrest (OHCA). A 66-year-old woman with witnessed ventricular fibrillation OHCA underwent successful venoarterial ECMO cannulation on scene in her bedroom floor by a mobile ECMO team under confined-space and ongoing CPR conditions. The operational significance is that it demonstrates feasibility of initiating ECMO before hospital arrival to reduce low-flow time in carefully selected OHCA patients.

Dinh K, Witkov R, Liu J et al. · ASAIO journal (American Society for Artificial Internal Organs : 1992) · (2026) · View on PubMed ↗

Global research trends in robotic surgery in andrology: a bibliometric and visualization analysis (2003-2025).

This bibliometric analysis evaluated global research trends in robotic surgery in andrology from 2003–2025 using Web of Science records and visualization tools (Biblioshiny and VOSviewer). The key finding was that publication output and citation patterns varied over time, with identifiable leading countries, authors, and collaboration networks across the 69 included studies. Scientifically and clinically, it maps where evidence and innovation are concentrated, helping guide future research priorities in robotic-assisted urologic/andrologic surgery.

Kaçan T, Öktem Ç, Bayraktar AB et al. · Journal of robotic surgery · (2026) · View on PubMed ↗

Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial.

This randomized clinical trial studied glucocorticoid users with glucocorticoid-induced osteoporosis, comparing sequential therapy with romosozumab (12 months) followed by denosumab (24 months) versus denosumab monotherapy (36 months) or bisphosphonate monotherapy. The key finding was that romosozumab followed by denosumab produced superior long-term efficacy compared with the alternative regimens. Clinically, it supports a sequential anti-sclerostin then anti-RANKL strategy to improve outcomes in patients whose bone loss is driven by ongoing glucocorticoid exposure.

Kawazoe M, Masuoka S, Kaneko K et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · (2026) · View on PubMed ↗

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo-Controlled, Phase III Trial.

This phase III randomized, placebo-controlled trial evaluated dupilumab (300 mg every 2 weeks) as add-on therapy to daily intranasal corticosteroids in Chinese adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) uncontrolled on standard care. The key finding was that dupilumab significantly improved nasal polyp score at week 24 and had an acceptable safety profile versus placebo. Clinically, it extends evidence for dupilumab’s efficacy and tolerability specifically in Chinese CRSwNP patients, supporting broader use in this population.

Xian M, Wang M, Zhao C et al. · Allergy · (2026) · View on PubMed ↗ · Free PDF ↗

Age-Dependent Remodeling of the Sciatic Nerve Proteome in 5xFAD Mice Can Be Attenuated by Exercise or Donepezil Treatment to Maintain Neuromuscular Function.

This study used tandem mass tag (TMT)-labeled proteomics to characterize age-dependent remodeling of the sciatic nerve proteome in 5xFAD mice and wild-type mice at 3, 4, and 7 months, and tested whether exercise or donepezil could attenuate changes. The key finding was that proteome remodeling in 5xFAD mice coincided with functional declines around 4 months and that both exercise and donepezil helped maintain neuromuscular function by mitigating these proteomic shifts. Scientifically, it links early peripheral nerve/mitochondrial pathway dysfunction to AD-like disease progression and suggests modifiable interventions for preserving neuromuscular performance.

Brisendine MH, Nieves-Esparcia DQ, Willoughby OS et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Single Interventions (Pharmacological or Renal Denervation) Are Not Sufficient to Achieve Blood Pressure Control in Resistant Hypertension a Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated whether adding a single intervention—either an additional pharmacological strategy or renal denervation (RDN)—can achieve blood pressure control in patients with true resistant hypertension. The key finding was that single interventions were not sufficient to reliably achieve target blood pressure control, based on pooled single-arm evidence across 68 included studies (n=6297). Clinically, it supports the need for multi-modal or more intensive strategies rather than relying on one added drug or RDN alone for resistant hypertension management.

Tsioufis K, Kyriakoulis KG, Vakka A et al. · Hypertension (Dallas, Tex. : 1979) · (2026) · View on PubMed ↗

Etomidate Versus Ketamine for Emergency Intubation in Critically Ill Patients: An Updated Meta-Analysis and Systematic Review.

This updated meta-analysis and systematic review compared etomidate versus ketamine as induction agents for emergency rapid sequence intubation in critically ill adults (≥18 years) using randomized controlled trials. The key findings focused on 28-day mortality and post-intubation hypotension, concluding that the two drugs differ in safety—particularly regarding hypotension risk—while efficacy outcomes were assessed across included RCTs. Clinically, the results inform drug selection for emergency intubation in ICU/ED settings where hemodynamic stability is critical.

Andriazzi VH, Curcio RP, Novais MARA et al. · Journal of intensive care medicine · (2026) · View on PubMed ↗

Long-term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large-cohort retrospective study.

This multicentre retrospective cohort study evaluated long-term outcomes of emicizumab prophylaxis in 132 patients with haemophilia A in China across 25 centers with follow-up of at least 1 year. The key findings were reductions in bleeding burden quantified by annualized bleeding rate (ABR) and annualized joint bleeding rate (AJBR), along with characterization of target joint status and adverse events over extended real-world use. The study provides important evidence for the effectiveness and safety of emicizumab in a resource-constrained setting and supports broader implementation.

Xu Y, Wang Y, Wang N et al. · British journal of haematology · (2026) · View on PubMed ↗

Impact of high versus low fraction of inspired oxygen for anaesthetic washout and extubation on postoperative pulmonary atelectasis formation and oxygenation: a randomised controlled trial.

The study compared high versus lower fractions of inspired oxygen (FiO2) during anesthetic washout and emergence/extubation to assess effects on postoperative pulmonary atelectasis and oxygenation in adults undergoing elective surgery. It found that using lower FiO2 (70% or 40%) during washout/extubation reduces atelectasis formation and improves oxygenation compared with 100% oxygen. This provides practical guidance for oxygen management around extubation to minimize postoperative lung complications.

Paschold BS, Braeuer BLP, Santer P et al. · British journal of anaesthesia · (2026) · View on PubMed ↗

Holmium Laser Enucleation of the Prostate Versus Robot-Assisted Simple Prostatectomy for Benign Prostatic Obstruction: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.

The study systematically reviewed and meta-analyzed comparative outcomes of holmium laser enucleation of the prostate (HoLEP) versus robot-assisted simple prostatectomy (RASP) for benign prostatic obstruction (BPO), using literature searches through August 2025 and applying trial sequential analysis. It concluded with an updated comparative assessment of perioperative and functional outcomes, while evaluating robustness via risk-of-bias and trial sequential methods. This evidence synthesis helps clinicians choose between HoLEP and RASP by clarifying which approach offers better overall outcomes for BPO.

Garcia GL, Pompeu BF, Barone GL et al. · Journal of laparoendoscopic & advanced surgical techniques. Part A · (2026) · View on PubMed ↗

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Across phase 3 REMIX-1 and REMIX-2 trials in adults with chronic spontaneous urticaria (CSU) symptomatic despite second-generation H1-antihistamines, remibrutinib (an oral, selective Bruton’s tyrosine kinase inhibitor) was evaluated for effects on disease control, sleep, and quality of life. Patients randomized 2:1 to remibrutinib 25 mg twice daily versus placebo for 24 weeks (followed by open-label treatment) showed improvements in patient-reported outcomes related to CSU burden. Clinically, demonstrating benefits beyond itch and wheals—such as sleep and QoL—supports remibrutinib as a patient-centered option for antihistamine-refractory CSU.

Mosnaim G, Saini S, Lebwohl M et al. · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · (2026) · View on PubMed ↗

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

This NCCN Guidelines Insights update summarizes the 2026 Version 3 recommendations for acute myeloid leukemia (AML) in adults, reflecting evidence from recently published clinical trials and prognostic biologic factors. It is not a single experimental study but a guideline synthesis intended to guide diagnosis and treatment decisions across AML subtypes. Clinically, the update helps standardize care and incorporate new trial-derived evidence into practice for a heterogeneous disease with high mortality.

Pollyea DA, Altman JK, Assi R et al. · Journal of the National Comprehensive Cancer Network : JNCCN · (2026) · View on PubMed ↗

Multimodal Prehabilitation for Older Adults Undergoing Spinal Fusion : A Randomized Clinical Trial.

This randomized clinical trial studied whether multimodal prehabilitation combined with Enhanced Recovery After Surgery (PREERAS) versus ERAS alone reduces 90-day postoperative complications in adults aged 75 years or older undergoing elective spinal fusion surgery in three tertiary hospitals in China. The key finding was not included in the provided abstract text, but the trial design specifically targeted postoperative complication outcomes as the primary endpoint. If PREERAS improves outcomes, it would be scientifically and clinically important as a scalable perioperative strategy to reduce risk in older surgical patients with limited physiologic reserve.

Wang S, Wang P, Li J et al. · Annals of internal medicine · (2026) · View on PubMed ↗

---

AI/ML methods in healthcare and biomedical research

Opportunities, risks and challenges integrating artificial intelligence into optometry education: A qualitative interview study.

This qualitative interview study explored stakeholder views on integrating artificial intelligence (AI) into optometry education among eyecare practitioners, students, educators, regulators, and AI technology experts. Thematic analysis (from semi-structured online interviews) identified opportunities, risks, and implementation challenges that must be addressed before AI content can be prioritized in the optometry curriculum. Establishing these educational priorities is significant for preparing future optometrists to use AI tools safely and effectively in clinical practice.

Buckmaster F, van Staden D, Coetzee L · Optometry and vision science : official publication of the American Academy of Optometry · (2026) · View on PubMed ↗

A hybrid CNN-LSTM approach for large-scale Twitter sentiment analysis with explainable artificial intelligence.

This study developed and evaluated a hybrid convolutional neural network–long short-term memory (CNN-LSTM) model for large-scale Twitter sentiment analysis with explainable AI. The key finding is that combining CNN local feature extraction with LSTM sequential/context modeling improves tweet sentiment classification while providing interpretability for model decisions. This is clinically and scientifically significant because it supports more reliable, transparent sentiment inference from short, informal social media text.

Kılıç Z, Aslan E, Ozupak Y · Scientific reports · (2026) · View on PubMed ↗

Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology.

This paper introduced CANVAS (cellular architecture and neighborhood-informed virtual AI-driven spatial profiling), an AI platform that infers tumor ecological habitats from hematoxylin and eosin (H&E) histopathology. Trained on an atlas of over 18 million cells profiled by 41-plex spatial proteomics across 457 non-small cell lung cancer patients, CANVAS identified 10 reproducible cellular neighborhoods (CNs) capturing conserved spatial organization. This is significant because it provides a scalable, virtual spatial profiling approach that can improve understanding of tumor microenvironment architecture from routine pathology slides.

Li Y, Li Z, Quinton R et al. · Cell · (2026) · View on PubMed ↗

Efficient prime editing in vivo and in vitro using lipid nanoparticles.

The study developed and optimized a systematic prime editing lipid nanoparticle (PE-LNP) delivery platform to improve prime editing efficiency in vivo and in vitro for the three-component prime editing system. The key finding is that cargo design bottlenecks can be addressed through an optimization workflow, yielding PE-LNPs with up to 49% average in vivo prime editing efficiency. This is significant because it advances non-viral, clinically relevant delivery for precise genome editing using prime editing in living systems.

Jiang AY, Cristian A, Brooks DL et al. · Nature nanotechnology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Aging biology and biological age measurement

Plasma proteomic signatures of cellular aging predict human disease.

This study used plasma proteomics from 60,542 individuals with measurements of over 7,000 proteins to build machine-learning models estimating biological age across more than 40 cell types. Plasma proteomic “cellular aging” signatures predicted incident disease and mortality over 15 years and identified that a subset of individuals shows accelerated aging in specific cell types, with APOE4 carriers tending toward older astral signatures. The work supports plasma proteomics as a scalable way to quantify cell type–specific aging risk and stratify future disease outcomes.

Ding DY, Bot VA, Chen KL et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Single-cell map of the healthy human immune system across the lifespan reveals unique infant immune signatures.

This study mapped the healthy human immune system across the lifespan by profiling PBMCs from 167 individuals aged 2 months to 105 years using single-cell RNA sequencing (scRNA-seq) and single-nucleus ATAC-seq (snATAC-seq). It identified age-associated immune remodeling patterns, including “rise and fall” dynamics for MAIT and γδ T cells and profound age-related shifts in conventional CD8+ T cells, with distinct signatures in infants and the oldest-old. These single-cell atlases provide reference immune trajectories that can improve interpretation of immune dysregulation in pediatric and age-related disease.

Nehar-Belaid D, Thibodeau A, Eroglu A et al. · Nature communications · (2026) · View on PubMed ↗

The senescence-stiffening loop: Extracellular matrix remodeling, hypoperfusion, and mitochondrial dysfunction drive tissue aging.

This mechanistic study investigated how extracellular matrix (ECM) remodeling, hypoperfusion, and mitochondrial dysfunction form a “senescence-stiffening loop” that drives tissue aging. It found that ECM stiffening from collagen crosslinking and elastin loss reduces vascular compliance and angiogenesis, leading to intermittent hypoxia that shifts transcriptomic/proteomic programs toward reduced oxidative phosphorylation and increased reactive oxygen species. The scientific significance is that it links vascular-ECM- mitochondrial dysfunction to a testable causal framework for tissue aging and potential intervention points.

Ferrucci L, Donega S, Herman AB et al. · Cell metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

---

Musculoskeletal and regenerative medicine (including DMD, TMJOA)

DMD-Null mice exhibit severe muscle weakness, impaired regeneration, and deficient satellite cell function.

This study examined dystrophic phenotypes in DMD-null (Dmd−/−) mice, focusing on muscle weakness, regeneration capacity, and satellite cell function. DMD-null mice showed severe muscle weakness with impaired regeneration and deficient satellite cell function compared with controls. These findings strengthen the DMD-null mouse as a more human-relevant model than mdx for testing therapies targeting satellite cell–mediated muscle repair in Duchenne muscular dystrophy.

Wilton-Clark H, Shah MNA, Leckie J et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

The YTHDC1-m6A-GADD45B axis promotes chondrogenesis of hPDLSCs via suppressing senescence through p53/p21 signalling pathway.

The study investigated how the m6A reader YTHDC1 regulates senescence and chondrogenesis in human periodontal ligament stem cells (hPDLSCs) under inflammatory conditions relevant to temporomandibular joint osteoarthritis (TMJOA). It found that the YTHDC1–m6A–GADD45B axis promotes chondrogenesis by suppressing senescence through p53/p21 signaling. These findings suggest targeting the YTHDC1–GADD45B pathway could improve cartilage regeneration by reducing stem-cell senescence in TMJOA.

Tan D, Tao Q, Ye L et al. · International journal of oral science · (2026) · View on PubMed ↗ · Free PDF ↗

Targeting the senescence‒autophagy axis via p16INK4a inhibition alleviates pulmonary fibrosis.

The study investigated whether inhibiting the senescence–autophagy axis via p16INK4a (p16) modulation can alleviate pulmonary fibrosis, using patient-derived transcriptomic data and multiple mouse models including naturally aging mice, bleomycin-induced fibrosis, and radiation-induced pulmonary fibrosis. It found that elevated p16INK4A is associated with impaired autophagic flux and that p16 inhibition improves senescence/autophagy dysfunction and reduces fibrosis progression. These results support p16INK4a as a mechanistic therapeutic target to restore autophagy and slow idiopathic pulmonary fibrosis.

Yoo YJ, Zhang M, Jin SH et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

---

Genetics, epigenetics, and development beyond humans (model organisms)

Ubiquitin-proteasome system regulates pro-crossover protein dynamics during meiosis in Caenorhabditis elegans.

In the nematode Caenorhabditis elegans, this study tested how the ubiquitin-proteasome system (UPS) regulates pro-crossover protein dynamics during meiosis. Knockdown of the ubiquitin-activating enzyme E1 or the proteasome increased pro-crossover protein levels and crossover designation, and impairing ubiquitination (rather than proteasome activity) was key to the observed effects on crossover patterning. This is significant because it clarifies UPS-dependent control of meiotic crossover formation, a fundamental process for accurate chromosome segregation.

Zhang H, Liang W, Li M et al. · PLoS biology · (2026) · View on PubMed ↗

Canonical EDS1/PAD4 small-molecule binding sites are required for LRR-RP-mediated pattern-triggered immunity.

This study investigated how canonical EDS1/PAD4 small-molecule binding sites regulate leucine-rich repeat receptor protein (LRR-RP)–mediated pattern-triggered immunity in plants. The key finding was that EDS1 and PAD4 small-molecule binding sites are required for proper LRR-RP signaling to mount pattern-triggered immunity. Scientifically, it clarifies a mechanistic link between EDS1/PAD4 ligand-binding and receptor-driven immune activation, informing how effector-triggered and pattern-triggered immunity pathways are coordinated.

Fliegmann J, Janocha D, Hua C et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

DNA methylation reprogramming in marsupial embryos is restricted to the extraembryonic lineage.

The study examined DNA methylation (5mC) reprogramming in marsupial embryos, focusing on which embryonic versus extraembryonic lineages undergo methylation changes. It found that 5mC reprogramming is restricted to the extraembryonic lineage rather than occurring broadly across embryonic tissues. This lineage-restricted epigenetic remodeling clarifies how marsupials achieve totipotency and parental-to-zygotic transition without the global 5mC erasure typical of eutherian mammals.

Angeloni A, Hammond JM, Peters TJ et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on June 17, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.